HLN vs. TAK: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at HLN and TAK, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
Both HLN and TAK are American Depositary Receipts (ADRs). This provides U.S. investors with straightforward access to investing in these foreign-listed companies.
| Symbol | HLN | TAK |
|---|---|---|
| Company Name | Haleon plc | Takeda Pharmaceutical Company Limited |
| Country | United Kingdom | Japan |
| GICS Sector | Consumer Staples | Health Care |
| GICS Industry | Personal Care Products | Pharmaceuticals |
| Market Capitalization | 43.85 billion USD | 48.39 billion USD |
| Exchange | NYSE | NYSE |
| Listing Date | July 25, 2022 | January 5, 2010 |
| Security Type | ADR | ADR |
Historical Performance
This chart compares the performance of HLN and TAK by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | HLN | TAK |
|---|---|---|
| 5-Day Price Return | 1.11% | 0.00% |
| 13-Week Price Return | -11.44% | 8.33% |
| 26-Week Price Return | -6.73% | 8.70% |
| 52-Week Price Return | -1.96% | 5.51% |
| Month-to-Date Return | 1.39% | 7.43% |
| Year-to-Date Return | -3.42% | 7.92% |
| 10-Day Avg. Volume | 10.79M | 4.55M |
| 3-Month Avg. Volume | 16.89M | 4.17M |
| 3-Month Volatility | 16.19% | 15.27% |
| Beta | 0.40 | 0.36 |
Profitability
Return on Equity (TTM)
HLN
3.26%
Personal Care Products Industry
- Max
- 31.59%
- Q3
- 20.42%
- Median
- 11.01%
- Q1
- 3.26%
- Min
- -18.42%
HLN’s Return on Equity of 3.26% is on par with the norm for the Personal Care Products industry, indicating its profitability relative to shareholder equity is typical for the sector.
TAK
1.48%
Pharmaceuticals Industry
- Max
- 38.59%
- Q3
- 19.84%
- Median
- 11.90%
- Q1
- 5.63%
- Min
- -9.96%
TAK’s Return on Equity of 1.48% is in the lower quartile for the Pharmaceuticals industry. This indicates a less efficient generation of profit from its equity base when compared to its competitors.
Net Profit Margin (TTM)
HLN
12.84%
Personal Care Products Industry
- Max
- 15.12%
- Q3
- 12.06%
- Median
- 9.26%
- Q1
- 5.50%
- Min
- -0.40%
A Net Profit Margin of 12.84% places HLN in the upper quartile for the Personal Care Products industry, signifying strong profitability and more effective cost management than most of its peers.
TAK
2.36%
Pharmaceuticals Industry
- Max
- 34.51%
- Q3
- 17.73%
- Median
- 12.12%
- Q1
- 5.99%
- Min
- -7.73%
Falling into the lower quartile for the Pharmaceuticals industry, TAK’s Net Profit Margin of 2.36% indicates weaker profitability. This means the company retains a smaller portion of each dollar in sales as profit compared to its competitors.
Operating Profit Margin (TTM)
HLN
19.64%
Personal Care Products Industry
- Max
- 19.80%
- Q3
- 17.96%
- Median
- 13.14%
- Q1
- 7.58%
- Min
- -4.25%
An Operating Profit Margin of 19.64% places HLN in the upper quartile for the Personal Care Products industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
TAK
7.48%
Pharmaceuticals Industry
- Max
- 41.53%
- Q3
- 23.00%
- Median
- 16.24%
- Q1
- 9.24%
- Min
- -6.94%
TAK’s Operating Profit Margin of 7.48% is in the lower quartile for the Pharmaceuticals industry. This indicates weaker profitability from core operations, which may stem from inefficiencies or competitive pressures on pricing.
Profitability at a Glance
| Symbol | HLN | TAK |
|---|---|---|
| Return on Equity (TTM) | 3.26% | 1.48% |
| Return on Assets (TTM) | 1.58% | 0.72% |
| Net Profit Margin (TTM) | 12.84% | 2.36% |
| Operating Profit Margin (TTM) | 19.64% | 7.48% |
| Gross Profit Margin (TTM) | 60.75% | 65.51% |
Financial Strength
Current Ratio (MRQ)
HLN
0.87
Personal Care Products Industry
- Max
- 4.26
- Q3
- 2.61
- Median
- 1.74
- Q1
- 1.13
- Min
- 0.76
HLN’s Current Ratio of 0.87 falls into the lower quartile for the Personal Care Products industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
TAK
1.01
Pharmaceuticals Industry
- Max
- 4.49
- Q3
- 2.77
- Median
- 1.74
- Q1
- 1.26
- Min
- 0.11
TAK’s Current Ratio of 1.01 falls into the lower quartile for the Pharmaceuticals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
Debt-to-Equity Ratio (MRQ)
HLN
0.53
Personal Care Products Industry
- Max
- 1.13
- Q3
- 0.63
- Median
- 0.26
- Q1
- 0.04
- Min
- 0.00
HLN’s Debt-to-Equity Ratio of 0.53 is typical for the Personal Care Products industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
TAK
0.65
Pharmaceuticals Industry
- Max
- 2.44
- Q3
- 1.07
- Median
- 0.42
- Q1
- 0.11
- Min
- 0.00
TAK’s Debt-to-Equity Ratio of 0.65 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
HLN
8.00
Personal Care Products Industry
- Max
- 96.53
- Q3
- 59.91
- Median
- 22.25
- Q1
- 7.85
- Min
- -1.93
HLN’s Interest Coverage Ratio of 8.00 is positioned comfortably within the norm for the Personal Care Products industry, indicating a standard and healthy capacity to cover its interest payments.
TAK
2.05
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 44.18
- Median
- 9.83
- Q1
- 2.82
- Min
- -42.71
In the lower quartile for the Pharmaceuticals industry, TAK’s Interest Coverage Ratio of 2.05 indicates a tighter cushion for servicing debt, suggesting less financial flexibility than many of its competitors.
Financial Strength at a Glance
| Symbol | HLN | TAK |
|---|---|---|
| Current Ratio (MRQ) | 0.87 | 1.01 |
| Quick Ratio (MRQ) | 0.63 | 0.52 |
| Debt-to-Equity Ratio (MRQ) | 0.53 | 0.65 |
| Interest Coverage Ratio (TTM) | 8.00 | 2.05 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
HLN
0.72%
Personal Care Products Industry
- Max
- 4.08%
- Q3
- 2.46%
- Median
- 1.82%
- Q1
- 0.83%
- Min
- 0.00%
HLN’s Dividend Yield of 0.72% is in the lower quartile for the Personal Care Products industry. This suggests the company’s strategy likely favors retaining earnings for growth over providing a high dividend income.
TAK
4.23%
Pharmaceuticals Industry
- Max
- 6.98%
- Q3
- 3.32%
- Median
- 2.13%
- Q1
- 0.14%
- Min
- 0.00%
With a Dividend Yield of 4.23%, TAK offers a more attractive income stream than most of its peers in the Pharmaceuticals industry, signaling a strong commitment to shareholder returns.
Dividend Payout Ratio (TTM)
HLN
954.40%
Personal Care Products Industry
- Max
- 207.61%
- Q3
- 115.17%
- Median
- 69.37%
- Q1
- 47.71%
- Min
- 0.00%
At 954.40%, HLN’s Dividend Payout Ratio is exceptionally high, exceeding the typical range for the Personal Care Products industry. While this provides a significant return to shareholders, it may limit funds for reinvestment and could be difficult to sustain.
TAK
138.69%
Pharmaceuticals Industry
- Max
- 165.20%
- Q3
- 90.59%
- Median
- 49.13%
- Q1
- 28.91%
- Min
- 0.00%
TAK’s Dividend Payout Ratio of 138.69% is in the upper quartile for the Pharmaceuticals industry. This indicates a strong commitment to shareholder returns but also suggests that a smaller portion of earnings is retained for reinvestment compared to many peers.
Dividend at a Glance
| Symbol | HLN | TAK |
|---|---|---|
| Dividend Yield (TTM) | 0.72% | 4.23% |
| Dividend Payout Ratio (TTM) | 954.40% | 138.69% |
Valuation
Price-to-Earnings Ratio (TTM)
HLN
22.43
Personal Care Products Industry
- Max
- 55.49
- Q3
- 36.75
- Median
- 26.49
- Q1
- 22.40
- Min
- 11.12
HLN’s P/E Ratio of 22.43 is within the middle range for the Personal Care Products industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
TAK
66.26
Pharmaceuticals Industry
- Max
- 42.51
- Q3
- 26.88
- Median
- 19.11
- Q1
- 15.12
- Min
- 0.00
At 66.26, TAK’s P/E Ratio is exceptionally high, exceeding the typical maximum for the Pharmaceuticals industry. This suggests the stock may be significantly overvalued compared to its peers and implies high market expectations that could be difficult to meet.
Price-to-Sales Ratio (TTM)
HLN
2.88
Personal Care Products Industry
- Max
- 5.35
- Q3
- 2.83
- Median
- 2.07
- Q1
- 1.13
- Min
- 0.00
HLN’s P/S Ratio of 2.88 is in the upper echelon for the Personal Care Products industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.
TAK
1.56
Pharmaceuticals Industry
- Max
- 7.55
- Q3
- 4.54
- Median
- 2.11
- Q1
- 1.52
- Min
- 0.00
TAK’s P/S Ratio of 1.56 aligns with the market consensus for the Pharmaceuticals industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio (MRQ)
HLN
2.11
Personal Care Products Industry
- Max
- 7.32
- Q3
- 5.26
- Median
- 2.93
- Q1
- 1.84
- Min
- 1.14
HLN’s P/B Ratio of 2.11 is within the conventional range for the Personal Care Products industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
TAK
1.01
Pharmaceuticals Industry
- Max
- 9.78
- Q3
- 4.96
- Median
- 2.23
- Q1
- 1.46
- Min
- 0.60
TAK’s P/B Ratio of 1.01 is in the lower quartile for the Pharmaceuticals industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
Valuation at a Glance
| Symbol | HLN | TAK |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 22.43 | 66.26 |
| Price-to-Sales Ratio (TTM) | 2.88 | 1.56 |
| Price-to-Book Ratio (MRQ) | 2.11 | 1.01 |
| Price-to-Free Cash Flow Ratio (TTM) | 15.04 | 10.08 |